Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1EYOF)

Drug Name
BT-200 Drug Info
Indication
Disease Entry ICD 11 Status REF
Von willebrand disease 3B12 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM1EYOF

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
von Willebrand factor (VWF) TT3SZBT VWF_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
von Willebrand factor (VWF) DTT VWF 3.459 8.185 6.67 8.541
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Von willebrand disease
ICD Disease Classification 3B12
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
von Willebrand factor (VWF) DTT VWF 2.96E-01 2.47 2.08
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04677803) A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Guardian Theapeutics